Clinical Trial Update: Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating infusion of donor-derived cytokine-induced killer (CIK) cells in patients with relapsed hematologic malignancies after haploidentical…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• donor-derived cytokine-induced killer (CIK) cells (cytokine-induced killer cells)

Snippet

Sponsor: A.O. Ospedale Papa Giovanni XXIII | Conditions: Relapsed Hematologic Malignancy | Phase 1, Phase 2 | Status: UNKNOWN